TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

Benzinga Logo Benzinga By Vandana Singh
Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

Gilead Sciences reported mixed results from a Phase 3 breast cancer study of Trodelvy, which did not meet its primary endpoint of progression-free survival but showed an early trend in overall survival. The drug's safety profile remained consistent with previous studies.

Insights
GILD   neutral

Study results were mixed - missed primary endpoint but showed potential early survival trend, indicating neither a clear success nor complete failure